Chuangui Chen

机构：Tianjin Medical University Cancer Institute and Hospital

发表论文 63 篇 · 总被引 628 次 · h-index 15

代表论文

• Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001) (2022 · Annals of Translational Medicine · 被引 62)
• Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002) (2022 · Frontiers in Oncology · 被引 61)
• A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial (2024 · Cancer Cell · 被引 53)
• Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random (2022 · Radiotherapy and Oncology · 被引 29)
• CXCR4 promotes the growth and metastasis of esophageal squamous cell carcinoma as a critical downstream mediator of HIF‐1α (2022 · Cancer Science · 被引 28)
• A nomogram to predict lymph node metastasis risk for early esophageal squamous cell carcinoma (2021 · BMC Cancer · 被引 23)